Table 2 Univariate survival analysis of osteosarcoma according to immunohistochemistry scores for HLA class I and other clinicopathologic factors
From: Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma
| Â | 3Â year overall survival rate | 3Â year disease free survival rate |
|---|---|---|
HLA class I | P < 0.0001 | P < 0.0001 |
   Negative | 0% | 0% |
   Low | 77.8% | 33.3% |
   High | 100% | 66.1% |
Age | P = 0.93 | P = 0.89 |
   ≤ 14 years | 83.3% | 33.3% |
   > 14 years | 60.4% | 44.4% |
Sex | P = 0.023 | P = 0.001 |
   Male | 80.9% | 51.9% |
   Female | 0% | 0% |
Tumor site | P = 0.60 | P = 0.081 |
   Lower femur | 85.7% | 38.1% |
   Middle femur | 0% | 0% |
   Upper tibia | 58.3% | 66.7% |
Tumor stage | P < 0.0001 | P < 0.0001 |
   Localized | 96.3% | 51.9% |
   Metastatic | 0% | 0% |
Histopathological variant | P = 0.13 | P = 0.413 |
   Osteoblastic | 39.3% | 50% |
   Chondroblastic | 37.5% | 25% |
   Fibroblastic | 100% | 55.6% |
   Small cell type | 100% | 0% |
Tumor necrosis | P = 0.017 | P < 0.0001 |
   Poor response (<90%) | 32.7% | 12.5% |
   Good response (≥90%) | 100% | 91.7% |